In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...

丹麦制药公司 诺和诺德 （ Novo Nordisk A/S ）周五报告称，该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限，而且有一定副作用，导致该公司股价周五下跌。

▎药明康德内容团队编辑NanoVation Therapeutics今日宣布与诺和诺德（Novo Nordisk）达成一项多年研发合作伙伴关系，旨在推进针对心脏代谢性疾病和罕见病的创新基因药物（genetic ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

The Senate investigation showed Americans pay $1,349 a month for the weight-loss drug Wegovy, which is priced at $92 in the United Kingdom.

周五早间 诺和诺德 Novo Nordisk股价一度下跌逾6%，此前有媒体报道称其减肥药的试验数据不佳。在减肥药物领域，诺和诺德面临着来自多家小公司和罗氏等制药巨头越来越激烈的竞争。

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top ...

（法新社巴黎11日电） 今天发布的1份小型研究报告显示，丹麦大药厂诺和诺德（Novo Nordisk）的减肥药善纤达（Saxenda）对有肥胖症的12岁以下儿童大致安全且有效。这份结果受到外部专家审慎欢迎。

坎托菲茨杰拉德公司：重申Novo Nordisk(NVO.US)评级，由增持调整至增持评级, 目标价由160.00美元调整至160.00美元。 诺和诺德（NVO.US）公司简介：诺和诺德公司成立于1923年，是一家全球领先的生物制药公司，总部位于丹麦。其目标是推动变革，战胜糖尿病和其他严重 ...